May 20 (Reuters) - Trevi Therapeutics Inc TRVI.O:
TREVI THERAPEUTICS ANNOUNCES ADDITIONAL ANALYSES FROM PHASE 2A RIVER TRIAL OF HADUVIO IN PATIENTS WITH REFRACTORY CHRONIC COUGH
Source text: ID:nPn2pbKB7a
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))